Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
KNSA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.56 - $28.15
Previous CloseN/A
Volume84.12K
Average Volume (3M)596.20K
Market Cap
$1.70B
Enterprise Value$1.58B
Total Cash (Recent Filing)$183.58M
Total Debt (Recent Filing)$9.86M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
May 06, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding42,009,500
10 Day Avg. Volume512,608
30 Day Avg. Volume596,197
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.01
Price to Cash Flow (P/CF)22.60
P/FCF Ratio22.80
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.73
Enterprise Value/Ebitda-35.63
Forecast
1Y Price Target
$35.40Price Target Upside51.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Kiniksa Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Commercial ProgressArcalyst commercial progress continues to impress with guidance in-line.
Growth OpportunitiesManagement expects continued growth to be driven by patients on second or greater recurrence, suggesting potential growth opportunities.
Bears Say
Clinical DevelopmentThe lack of clinical catalysts in 2025 means Arcalyst will be the main driver of the stock in the near term.
Market ConcernsShares are down, likely driven by fears that Arcalyst growth might be slowing down based on the quarter-on-quarter numbers.
---
Ownership Overview
7.81% Insiders
19.28% Mutual Funds
45.62% Other Institutional Investors
13.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KNSA FAQ
What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $16.56 and its highest was $28.15 in the past 12 months.
What is Kiniksa Pharmaceuticals’s market cap?
Kiniksa Pharmaceuticals’s market cap is $1.70B.
When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
Kiniksa Pharmaceuticals’s upcoming earnings report date is May 06, 2025 which is in 42 days.
How were Kiniksa Pharmaceuticals’s earnings last quarter?
Kiniksa Pharmaceuticals released its earnings results on Feb 25, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of $0.024 by -$0.144.
Is Kiniksa Pharmaceuticals overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals pay dividends?
Kiniksa Pharmaceuticals does not currently pay dividends.
What is Kiniksa Pharmaceuticals’s EPS estimate?
Kiniksa Pharmaceuticals’s EPS estimate is 0.02.
How many shares outstanding does Kiniksa Pharmaceuticals have?
Kiniksa Pharmaceuticals has 42,009,500 shares outstanding.
What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
Kiniksa Pharmaceuticals reported an EPS of -$0.12 in its last earnings report, missing expectations of $0.024. Following the earnings report the stock price went up 0.458%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
Currently, no hedge funds are holding shares in KNSA
---
Kiniksa Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.40 (51.54% Upside)
$35.40 (51.54% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.97%
12-Months-Change
Fundamentals
Return on Equity
-9.85%
Trailing 12-Months
Asset Growth
10.30%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
---
KNSA Company Deck
---
KNSA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and development progress, particularly with ARCALYST and the new KPL-387 program. However, the call also noted some challenges, including a net loss for the year and the discontinuation of abiprubart development. Despite these challenges, the company's strong financial position and future growth prospects offer a positive outlook.Read More>---
KNSA Stock 12 Month Forecast
Average Price Target
$35.40
▲(51.54% Upside)
Technical Analysis
Best Analysts Covering KNSA
1 Year
1 Year Success Rate
9/13 ratings generated profit
1 Year Average Return
+15.60%
reiterated a buy rating 28 days ago
Copying Paul Choi's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +15.60% per trade.
---